Eupraxia Pharmaceuticals Inc.

NASDAQ:EPRX

Biotechnology

Healthcare
$6.21 +1.11%

+$0.07 today

Market cap
$417.57M
Beta
1.48
P/E (TTM)
-8.5
EPS (TTM)
-$0.74
52W Low $4.19High $9.32

Volume 1.21M

Average 0.22M

EPRX Net Receivables

Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.

Eupraxia Pharmaceuticals Inc.NASDAQ: EPRX

Net Receivables · Q1 FY2026 · quarter ended Mar 2026

Net receivables rises 179.0% from a year ago

Net receivables stood at $665.42K at the end of Q1 FY2026, up 179.0% from a year earlier and down 1.3% from the prior quarter.

Context

  • Net receivables amounted to 0.5% of total assets at the end of Q1 FY2026, down 0.4 pp from a year earlier.
  • Net receivables increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net receivables keeps rising in the next quarterly balance sheet after a +179.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$665.42K-1.3% QoQ
Last fiscal yearDec 2025
$674.23K+194.6% YoY
Year agoMar 2025
$238.53K+179.0% since
Net Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+179.0%——
1 year+194.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Receivables history

Mixed currencies · from the balance sheet

Latest · FY2025
674.23K USD
Year-over-year change
+194.6%

Net Receivables vs competitors

How EPRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +179.0% is the 2nd highest of 6, against a peer median of -25.0%.
  • Net receivables amounts to 0.5% of total assets for EPRX, versus a peer median of 0.1%.
EPRX Competitors
Net Receivables for EPRX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IVAInventiva S.A.Dec 2025€9.12M EUR-25.0%+219.7%3.7%
MDWDMediWound Ltd.Mar 2026$2.75M USD-46.9%-37.5%3.4%
TARAProtara Therapeutics, Inc.Mar 2026$1.52M USD+312.2%+37.3%0.8%
EPRXEupraxia Pharmaceuticals Inc.Mar 2026$665.42K USD+179.0%—0.5%
RNACCartesian Therapeutics, Inc.Mar 2026$261K USD-85.2%-51.6%0.1%
NTHINeonc Technologies Holdings, Inc.Mar 2026$138.25K USD——4.2%
OBIOOrchestra BioMed Holdings, Inc.Mar 2026$84K USD-5.6%-0.3%0.1%
SLSSELLAS Life Sciences Group, Inc.Sep 2026$0 USD——0.0%
NAUTNautilus Biotechnology, Inc.Mar 2026$0 USD——0.0%
AARDAardvark Therapeutics, Inc. Common StockMar 2026$0 USD——0.0%
Peer median (excluding EPRX) —-25.0%-0.3%0.1%

Competitors are the stored peer set for EPRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

Mixed currencies
Metric
FY2021
Dec 2021 · CAD
FY2022
Dec 2022 · CAD
FY2023
Dec 2023 · USD
FY2024
Dec 2024 · USD
FY2025
Dec 2025 · USD
Cash & Equivalents20.89M24.73M14.56M33.1M80.56M
Short-term Investments9.01M0000
Net Receivables00143.52K228.87K674.23K
Inventory00000
Other Current Assets429.72K121.47K000
Total Current Assets30.6M25.17M14.91M34.44M85.1M
Property, Plant & Equipment (Net)589.07K718.61K343.52K424.92K987.13K
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets31.37K3.37K5.2K80.76K64.33K
Total Non-current Assets620.44K721.98K348.72K505.68K1.05M
Total Assets31.22M25.89M15.26M34.94M86.15M
Account Payables00000
Short-term Debt94.92K107.53K7.83M078.31K
Tax Payables0027.42K00
Deferred Revenue00000
Other Current Liabilities5.01K21.66K646.48K1.49M(78.31K)
Total Current Liabilities2.27M4.14M14.59M3.1M5.63M
Long-term Debt9.7M11.92M000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities9.84M11.99M0075.91K
Total Liabilities12.1M16.13M14.59M3.1M5.7M
Common Stock77.65M96.13M69.96M116.36M195.41M
Retained Earnings(74.26M)(104.63M)(79.43M)(131M)(169.58M)
Accumulated OCI16.56M(3.77M)(2.04M)(4.16M)(2.04M)
Other Stockholders Equity0(931)000
Minority Interest(833.84K)(783.49K)(996.78K)(1.57M)(1.6M)
Total Equity19.12M9.76M671.86K31.84M80.45M
Total Debt9.99M12.17M7.87M71.86K154.36K
Net Debt(10.9M)(12.56M)(6.69M)(33.03M)(80.41M)

Eupraxia Pharmaceuticals Inc.

NASDAQ:EPRX

Intrinsic Alpha fair value

Locked

Current Price

$6.21

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.